BRUIN CLL-313 showed significantly longer progression-free survival vs bendamustine plus rituximab, bringing a noncovalent BTK inhibitor to first-line care.
|Articles|June 1, 2007
- Volume 0 0
INDIAN FIRMS MUSCLING IN ON US MARKET
Advertisement
India?s bustling pharmaceutical industry is carving an increasingly noticeable niche in the generic drug market as big money prescription medicines lose patent protection in the United States. According to one recent analysis, 12 Indian drug manufacturers (including Aurobindo Pharma Ltd, Wockhardt, Ranbaxy Pharmaceuticals Inc, Dr Reddy?s Laboratories Ltd, and Sun Pharmaceutical Industries Ltd) have managed to snag almost 25% of all US generic drug approvals issued by the FDA during the first 4.5 months of 2007. During the same period last year, Indian firms accounted for less than 17% of US generic drug approvals.
Articles in this issue
over 19 years ago
otc Product Newsover 19 years ago
Pregnancy OK with Rheumatoid Arthritisover 19 years ago
OUT-OF-RANGE INRs COMMON AMONG WARFARIN PATIENTS IN ERover 19 years ago
case STUDIESover 19 years ago
THE DEBATE CONTINUES ON LENGTH OF THERAPYover 19 years ago
METABOLIC SYNDROME MAY CONTRIBUTE TO RISK OF VTEover 19 years ago
can you READ these Rxs?over 19 years ago
Reducing Drug Interaction Alerts: Not So Easyover 19 years ago
compounding HOTLINEover 19 years ago
Meeting the Needs of the Hospice PatientAdvertisement
Related to this article
A behavioral walking program matched supervised aerobic training for improving asthma control in a randomized trial of physically inactive adults.
Phase 2b data from EASD 2026 show the amylin-incretin combination also cut HbA1c by up to 2.9% in adults with obesity or overweight and type 2 diabetes.
American Pharmacists Month kicked off on October 1, honoring more than 700,000 pharmacy professionals and 250 years of caring for America's communities.
fMRI data show cagrilintide-semaglutide altered brain responses to high-calorie food cues; REIMAGINE analyses point to ectopic fat and bone effects.
Decades after cisplatin's approval, platinum-based chemotherapy continues to anchor treatment regimens across tumor types, new research finds.
A pharmacist-led collaborative drug therapy management program at NYC Health + Hospitals/Bellevue reported high patient satisfaction, and every surveyed patient said they felt respected and supported by their pharmacist.
A Novo Nordisk–funded claims analysis of adults with type 2 diabetes found an adjusted HR of 1.06 for MACE with switching, although the findings cannot show causation.
Advertisement
Advertisement
Trending on Pharmacy Times
1
EloraTZP Delivers Up to 23.3% Weight Loss in Adults With Obesity and T2D
2
Pharmacists Key to Lp(a) Counseling and Lipid Optimization
3
Why Lp(a) Testing Lagged Behind LDL Cholesterol Screening
4
What the 2025-2030 Dietary Guidelines Mean for Heart Health
5